PanGenex Corporation (“PanGenex” or “the Company”) (Pink Sheets: PGCX), a nutraceutical and dietary supplement developer, announced today that it has engaged Philips Sales & Marketing, Inc. (PSM) as its agent to sell its products through mail order catalogs, small chain stores including independent health food stores and pharmacies as well as three of the nation’s largest drug store chains. PSM will also provide marketing and advertising services for the Company.

The Company has allotted a marketing and advertising budget to build brand awareness and drive sales of its nutraceutical products. “We are excited to work with PSM because of their extensive experience in marketing and distributing nutraceutical products to the nation’s largest pharmacy retailers,” stated John Stanton, Chairman of PanGenex.

Brett Phillips, President of Phillips Sales & Marketing stated, "We are very impressed with PanGenex’s line of quality products and the professional staff they have assembled to supply our pipe line with cutting edge health products that should offer nutritional and health benefits to potentially millions of people not just in the U.S. but abroad as well.

About Phillips Sales & Marketing, Inc.

Phillips Sales & Marketing, Inc. advertises, markets and distributes proprietary and non-proprietary nutraceutical and dietary supplements and other nondurable consumer products. PSM is a vendor for the largest retail pharmacy chains in the United States as well as smaller independent drug and health food stores and maintains relationships with independent brokers representing product specific mail order catalogs. PSM’s unique ad campaign is designed to educate and engage the target audience to procure sales while providing the client with highly advantageous rates.

About PanGenex Corporation

PanGenex Corporation pursues business opportunities in the $70 billion nutraceutical and dietary supplement industry. With a focus on the cardiovascular health segment, PanGenex develops and markets sector-leading, patented or patent-pending, condition-specific nutraceuticals and topical over-the-counter (OTC) drugs and personal care products. PanGenex principal products Calci-Clear, LIPIDEME and Omeganol, address Soft Tissue Calcification (STC), an abnormal hardening or thickening of soft tissues (such as arteries) which is linked to over 50% of chronic diseases and presently affects an estimated 196 million or 60 percent of all Americans. Many of its products contain the purest grade of nutraceutical components available anywhere without a prescription. Since 2006, PanGenex has voluntarily submitted its product labels to the FDA without incidence. PanGenex products are sold to healthcare practitioners in 20 U.S. states, Canada, Puerto Rico, Canada, Brazil and Australia, in fine retail establishments and on the Internet at www.HeartHealthyWorld.com.

This press release contains "forward-looking statements," which are statements related to future, not past, events. In this context, the forward-looking statements often include statements regarding our goals, plans, projections and guidance regarding our financial position, results of operations, market position, pending and potential future acquisitions and business strategy, and often contain words such as "expects," "anticipates," "intends," "plans," "believes," "seeks" or "will." Any such forward-looking statements are not assurances of future performance and involve risks and uncertainties that may cause results to differ materially from those set forth in the statements. These risks and uncertainties include, among other things, (a) general economic and business conditions, (b) the level of strategic partner incentives, (c) the future regulatory environment, (d) our cost of financing, (e) our ability to complete acquisitions and dispositions and the risks associated therewith, and (f) our ability to retain key personnel. These factors, as well as additional factors, could affect our forward-looking statements. We urge you to carefully consider this information. We undertake no duty to update our forward-looking statements, including our earnings outlook. The statements in this press release have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.